EUROPE BOTANICAL AND PLANT DERIVATIVE DRUG MARKET FORECAST 2017-2025

NEW YORK, Oct. 23, 2017 /PRNewswire/ -- KEY FINDINGS
The Europe botanical and plant derivative drug market is predicted to be worth $9217 million by the end of 2025. The market is expected to grow at a CAGR of 2.81%, over the forecast period of 2017-2025.

Read the full report: https://www.reportlinker.com/p05155341

MARKET INSIGHTS
Increasing demand for traditional medicines, their growing applications in diseases and the increasing number of approvals from the FDA are chiefly responsible for driving the market growth. The rising prevalence of asthma is likely to augment the demand for botanical drugs in the European market. The market is segmented on the basis of products, therapeutic applications, and types. The various types of botanical and plant derivative drugs include glycosides, steroids, terpenes, and phenols. In order to develop botanical drugs in Europe, the manufacturer has to file an Investigational New Drug application (IND), and the drug has to undergo a number of clinical trials before it is approved to be sold in the market.

COMPETITIVE INSIGHTS
Bristol-Myers Squibb, Novartis International Ag, Glenmark Pharmaceuticals Ltd, Pfizer, GlaxoSmithKline, Medigene, Abbott, Eli Lilly And Company, Bayer Healthcare, Tasly Pharmaceuticals Inc, and Piramal Phytocare Ltd are some of the eminent companies operating in this market.

Read the full report: https://www.reportlinker.com/p05155341

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com

_________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/europe-botanical-and-plant-derivative-drug-market-forecast-2017-2025-300541375.html

SOURCE Reportlinker